gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Solute carrier family 18

VMAT2, vesicular monoamine transporter 2
The vesicular monoamine transporter acts to accumulate cytosolic monoamines into synaptic vesicles, using the proton gradient maintained across the synaptic vesicular membrane. Its proper function is essential to the correct activity of the monoaminergic systems that have been implicated in several human neuropsychiatric disorders. The transporter is a site of action of important drugs, including reserpine and tetrabenazine (summary by Peter et al., 1993 [PubMed 7905859]). See also SLC18A1 (MIM 193002).[supplied by OMIM, Jan 2011] (from NCBI)
Top mentioned proteins: CAN, ACID, HAD, AGE, V1a
Papers on VMAT2
The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine.
Salamone et al., United States. In Behav Brain Res, Mar 2016
Via inhibition of the vesicular monoamine transporter (VMAT-2), TBZ blocks dopamine (DA) storage and depletes striatal DA; this drug also has been shown to induce Parkinsonian motor side effects in patients.
Position Emission Tomography/Single-Photon Emission Tomography Neuroimaging for Detection of Premotor Parkinson's Disease.
Wang et al., Guangzhou, China. In Cns Neurosci Ther, Feb 2016
For example, dopaminergic dysfunctions can be identified by detecting the expression of vesicular monoamine transporter (VMAT2) and aromatic amino acid decarboxylase (AADC) to evaluate the conditions of dopaminergic terminals functions in high-risk individuals of PD.
High-mesembrine Sceletium extract (Trimesemine™) is a monoamine releasing agent, rather than only a selective serotonin reuptake inhibitor.
Smith et al., Stellenbosch, South Africa. In J Ethnopharmacol, Feb 2016
MATERIALS AND METHODS: Human astrocytes and mouse hippocampal cells were treated with citalopram or Sceletium extract for 15 and 30min, after which protein expression levels of serotonin transporter (SERT) and vesicular monoamine transporter-2 (VAMT-2) was assessed using fluorescent immunocytochemistry and digital image analysis.
Effects of oxytocin on adreno-medullary catecholamine synthesis, uptake and storage in rats exposed to chronic isolation stress.
Dronjak et al., Belgrade, Serbia. In Endocr Res, Feb 2016
MATERIALS AND METHODS: In the present study, we examined the effect of chronic oxytocin treatment on the level of plasma catecholamine and its content, mRNA and protein levels of tyrosine hydroxylase (TH), norepinephrine transporter (NET) as well as vesicular monoamine transporter 2 (VMAT2) in the adrenal medulla of socially isolated rats.
Harnessing the Trophic and Modulatory Potential of Statins in a Dopaminergic Cell Line.
Garcia-Ladona et al., Braine-le-Comte, Belgium. In Synapse, Jan 2016
Statins increased the levels of presynaptic dopaminergic biomarkers such as vesicular monoamine transporter 2 (VMAT2), synaptic vesicle glycoproteins 2A and 2C (SV2C) and synaptogyrin-3 (SYNGR3).
Histidine decarboxylase and urinary methylimidazoleacetic acid in gastric neuroendocrine cells and tumours.
Janson et al., Uppsala, Sweden. In World J Gastroenterol, Jan 2016
METHODS: Control tissues from fundus (n = 3) and corpus (n = 3) mucosa of six patients undergoing operations for gastric adenocarcinoma, biopsy and/or gastric surgical specimens from 64 patients with primary gastric neuroendocrine tumours (GNETs), as well as metastases from 22 of these patients, were investigated using conventional immunohistochemistry and double immunofluorescence with commercial antibodies vs vesicular monoamine transporter 2 (VMAT-2), HDC and ghrelin.
Pathological gamma oscillations, impaired dopamine release, synapse loss and reduced dynamic range of unitary glutamatergic synaptic transmission in the striatum of hypokinetic Q175 Huntington mice.
Grantyn et al., Magdeburg, Germany. In Neuroscience, Jan 2016
As a potential cause of hypokinesia, HD mice revealed a strong reduction in striatal KCl-induced dopamine release, accompanied by a decrease in the number of tyrosine hydroxylase-(TH)- and VMAT2-positive synaptic varicosities.
Protein cysteine S-nitrosylation inhibits vesicular uptake of neurotransmitters.
Wang et al., Winnipeg, Canada. In Neuroscience, Jan 2016
In the central nervous system, vesicular monoamine transporter 2 (VMAT2) is responsible for the uptake of monoamines, vesicular acetylcholine transporter (VAChT) is responsible for the uptake of acetylcholine, while vesicular glutamate transporters 1 and 2 (VGLUT1 and VGLUT2) are responsible for the uptake of glutamate.
Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.
Fleckenstein et al., Salt Lake City, United States. In Pharmacol Rev, Oct 2015
DA signaling and distribution are primarily modulated by the DA transporter (DAT) and by vesicular monoamine transporter (VMAT)-2, which transport DA into presynaptic terminals and synaptic vesicles, respectively.
NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.
Castro-Gayol et al., San Diego, United States. In Mov Disord, Oct 2015
NBI-98854 is a novel, highly selective, vesicular monoamine transporter 2 inhibitor.
The neuroprotective role of vesicular monoamine transporter 2 in neurodegenerative diseases.
Kilic et al., İstanbul, Turkey. In Med Chem, 2014
However, vesicular monoamine transporter-2 (VMAT-2) has been shown to be responsible for removing of neurotransmitters such as dopamine that may secondarily lead to a neuroprotective activity by different neurodegeneration models.
Brain dopaminergic system changes in drug addiction: a review of positron emission tomography findings.
Tian et al., Hangzhou, China. In Neurosci Bull, 2014
In this article, we review the major findings from PET imaging studies on the involvement of DA in drug addiction, including presynaptic DA synthesis, vesicular monoamine transporter 2, the DA transporter, and postsynaptic DA receptors.
Brain dopamine-serotonin vesicular transport disease and its treatment.
Minassian et al., Toronto, Canada. In N Engl J Med, 2013
We describe a disease encompassing infantile-onset movement disorder (including severe parkinsonism and nonambulation), mood disturbance, autonomic instability, and developmental delay, and we describe evidence supporting its causation by a mutation in SLC18A2 (which encodes vesicular monoamine transporter 2 [VMAT2]).
Dopaminergic neurons inhibit striatal output through non-canonical release of GABA.
Sabatini et al., Boston, United States. In Nature, 2012
Instead, GABA release requires activity of the vesicular monoamine transporter VMAT2, which is the vesicular transporter for dopamine.
Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity.
Segura-Aguilar et al., Santiago, Chile. In Biochim Biophys Acta, 2012
These results support our hypothesis that VMAT-2 and DT-diaphorase are an important defense system against aminochrome formed during dopamine oxidation.
Stimulation of vesicular monoamine transporter 2 activity by DJ-1 in SH-SY5Y cells.
Iguchi-Ariga et al., Sapporo, Japan. In Biochem Biophys Res Commun, 2012
These results indicate that wild-type DJ-1, but not Parkinson's disease-derived mutant DJ-1, stimulates VMAT2 activity and that C106 is necessary for the stimulating activity of DJ-1 toward VMAT2.
Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences.
Mongeau et al., Paris, France. In Neuropsychopharmacology, 2011
In an aversive ultrasound-induced defense paradigm, VMAT2(sert-cre) transgenic mice displayed a major increase in escape-like behaviors.
The predominant distribution of vesicular monoamine transporter 2 in the α cells and δ cells, not β cells, in rat islets.
Zhu et al., In Pancreas, 2011
Letter: report predominant expression of VMAT2 in pancreatic alpha/delta cells but not in pancreatic beta cells.
Platelet vesicular monoamine transporter 2 density in the disruptive behavior disorders.
Toren et al., Israel. In J Child Adolesc Psychopharmacol, 2011
there is no difference in levels of vesicular monoamine transporter 2 between children with disruptive behavior disorders and healthy volunteers
New insights into the mechanism of action of amphetamines.
Hanson et al., Salt Lake City, United States. In Annu Rev Pharmacol Toxicol, 2006
Plasmalemmal and vesicular monoamine transporters, such as the neuronal dopamine transporter and the vesicular monoamine transporter-2, are two of its principal targets.
share on facebooktweetadd +1mail to friends